The FDA has approved Eli Lilly's oral selective oestrogen receptor degrader (SERD) imlunestrant as a treatment for relapsed or refractory advanced breast cancer with a specific mutation in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback